Page last updated: 2024-11-13

ly 355703

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cryptophycin 52: an antimitotic antitumor agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	76210638
SCHEMBL ID	12092132
MeSH ID	M0294252

Synonyms (10)

Synonym
ly 355703
cryptophycin 52
cyclo(2,2-dimethyl-beta-alanyl-(2s)-2-hydroxy-4-methylpentanoyl-(2e,5s,6s)-5-hydroxy-6-((2r,3r)-3-phenyloxiranyl)-2-heptenoyl-3-chloro-o-methyl-d-tyrosyl)
ly355703
ly-355703
unii-i7fq5a183l
186256-67-7
i7fq5a183l ,
SCHEMBL12092132
(3s,10r,13e)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" Pharmacokinetic parameters were computed using noncompartmental methods."	( Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors. Boinpally, RR; Corbett, TH; Horwitz, JP; Jasti, BR; Kushner, J; Parchment, RE; Polin, L; White, K; Wiegand, RA; Zhou, SL, 2003)	0.32

Dosage Studied

Excerpt	Relevance	Reference
" Twice-weekly dosing did not allow improvement in dose intensity or tolerability."	( Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Algazy, K; Ellis, D; Enas, N; Gallagher, M; Hahn, S; Johnson, R; O'Dwyer, PJ; Schuchter, L; Stevenson, JP; Sun, W; Thornton, D; Vaughn, D, 2002)	0.31

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (14.29)	18.2507
2000's	19 (67.86)	29.6817
2010's	2 (7.14)	24.3611
2020's	3 (10.71)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.18 (24.57)
Research Supply Index	3.58 (2.92)
Research Growth Index	4.76 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.18)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (12.90%)	5.53%
Reviews	2 (6.45%)	6.00%
Case Studies	1 (3.23%)	4.05%
Observational	0 (0.00%)	0.25%
Other	24 (77.42%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
hexobarbital Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.	2.01	1	0	barbiturates
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	2.01	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.01	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.05	1	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
4-butyrolactone 4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.	2.01	1	0	butan-4-olide	metabolite; neurotoxin
tetrahydrofuran oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.	2.01	1	0	cyclic ether; oxolanes; saturated organic heteromonocyclic parent; volatile organic compound	polar aprotic solvent
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.43	2	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.05	1	0	1,2,3-triazole
cryptophycin cryptophycin: a potent antitumor cyclic depsipeptide active against drug-resistant cells; from cyanobacteria (blue-green algae) of the genus Nostoc; structure given in first source;	4.08	3	1
sesquiterpenes [no description available]	2.05	1	0
caulerpenyne caulerpenyne: from the marine algae Caulerpa taxifolia; structure in first source	2.05	1	0
hemiasterlin hemiasterlin: structure in first source	2.02	1	0
cryptophycin 1 [no description available]	3.21	1	0
phomopsin phomopsin: RN for cpd not in Chemline 7/18/83	2.02	1	0	oligopeptide
staurosporine staurosporinium : Conjugate acid of staurosporine.	2.01	1	0	ammonium ion derivative
dolastatin 10 dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.	2.02	1	0	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent
plitidepsin plitidepsin: a cyclodepsipeptide isolated from Aplidium albicans; has a pyruvoyl-proline residue instead of the lactyl-proline residue found in the linear peptide moiety of didemnin B. plitidepsin : A didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans.	3.21	1	0	didemnin	anticoronaviral agent; antineoplastic agent; marine metabolite
elisidepsin elisidepsin: antineoplastic; structure in first source. elisidepsin : A synthetic cyclodepsipeptide derived from a marine metabolite that exhibits antineoplastic properties.	3.21	1	0	cyclodepsipeptide	antineoplastic agent
cryptophycin 55 cryptophycin 55: chlorohydrin prodrug to cryptophycin 52	4.04	4	0
kahalalide f kahalalide F: a cyclodepsipeptide toxin; isolated from a mollusk, Elysia rubefescens; exhibits antitumoral activity against cell lines of colon cancer and prostatic cancer; structure given in first source	3.21	1	0

Condition	Relationship Strength	Studies	Trials
Cancer of Lung [description not available]	4.12	3	1
Lung Neoplasms Tumors or cancer of the LUNG.	4.12	3	1
Experimental Neoplasms [description not available]	2.25	1	0
Cutaneous T-Cell Lymphoma [description not available]	3.03	1	0
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	3.03	1	0
Benign Neoplasms [description not available]	4.36	2	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.36	2	2
Adenocarcinoma, Basal Cell [description not available]	4.09	3	1
Cancer of Colon [description not available]	2.01	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	4.09	3	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.01	1	0
Cancer of Prostate [description not available]	2.01	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.01	1	0
Carcinoma, Non-Small Cell Lung [description not available]	3.4	1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.4	1	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.01	1	0
Experimental Mammary Neoplasms [description not available]	2.41	2	0
Cancer of Pancreas [description not available]	2.01	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.01	1	0
Leukemia L 1210 [description not available]	2	1	0
Encephalopathy, Toxic [description not available]	2	1	0
Vulvitis Inflammation of the VULVA. It is characterized by PRURITUS and painful urination.	2	1	0
Acute Disease Disease having a short and relatively severe course.	2	1	0
Carcinoma, Anaplastic [description not available]	2	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2	1	0

chemdatabank.com